` OCS (Oculis Holding AG) vs S&P 500 Comparison - Alpha Spread

O
OCS
vs
S&P 500

Over the past 12 months, OCS has significantly outperformed S&P 500, delivering a return of +50% compared to the S&P 500's +13% growth.

Stocks Performance
OCS vs S&P 500

Loading
OCS
S&P 500
Add Stock

Performance Gap
OCS vs S&P 500

Loading
OCS
S&P 500
Difference
www.alphaspread.com

Performance By Year
OCS vs S&P 500

Loading
OCS
S&P 500
Add Stock

Competitors Performance
Oculis Holding AG vs Peers

Oculis Holding AG
Glance View

Market Cap
972.3m USD
Industry
Pharmaceuticals

Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improve eye care. The company is headquartered in Zug, Zug and currently employs 28 full-time employees. The firm is focused on the development of eye disease treatment for ophthalmology. The company includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The firm have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.

OCS Intrinsic Value
Not Available
O
Back to Top